Trial · NCT03525886
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages | Cohort 1 (50 mg QHS) | -60 | Inter-Quartile Range -85 to -32 | Percent (%) | |
| Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages | Cohort 2 (100 mg QHS) | -58 | Inter-Quartile Range -93 to 8 | Percent (%) | |
| Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages | Cohort 3 (100 mg QPM) | -53 | Inter-Quartile Range -86 to -43 | Percent (%) | |
| Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages | Cohort 4 (100 mg BID) | -64 | Inter-Quartile Range -86 to -51 | Percent (%) | |
| Percent Change From Baseline to Day 14 in Androstenedione Morning Window Averages | Cohort 1 (50 mg QHS) | -21 | Inter-Quartile Range -55 to -7 | Percent (%) | |
| Percent Change From Baseline to Day 14 in Androstenedione Morning Window Averages | Cohort 2 (100 mg QHS) | -42 | Inter-Quartile Range -70 to -23 | Percent (%) | |
| Percent Change From Baseline to Day 14 in Androstenedione Morning Window Averages | Cohort 3 (100 mg QPM) | -51 | Inter-Quartile Range -70 to 50 | Percent (%) | |
| Percent Change From Baseline to Day 14 in Androstenedione Morning Window Averages | Cohort 4 (100 mg BID) | -64 | Inter-Quartile Range -68 to -52 | Percent (%) | |
| Percent Change From Baseline to Day 14 in Adrenocorticotropic Hormone (ACTH) Morning Window Averages | Cohort 1 (50 mg QHS) | -54 | Inter-Quartile Range -75 to -32 | Percent (%) | |
| Percent Change From Baseline to Day 14 in Adrenocorticotropic Hormone (ACTH) Morning Window Averages | Cohort 2 (100 mg QHS) | -63 | Inter-Quartile Range -80 to -39 | Percent (%) | |
| Percent Change From Baseline to Day 14 in Adrenocorticotropic Hormone (ACTH) Morning Window Averages | Cohort 3 (100 mg QPM) | -64 | Inter-Quartile Range -87 to -3 | Percent (%) | |
| Percent Change From Baseline to Day 14 in Adrenocorticotropic Hormone (ACTH) Morning Window Averages | Cohort 4 (100 mg BID) | -66 | Inter-Quartile Range -78 to -47 | Percent (%) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03525886/results